about
Adverse events in patients taking macrolide antibiotics versus placebo for any indicationOral anti-pseudomonal antibiotics for cystic fibrosisCurrent and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implicationsKey mechanisms governing resolution of lung inflammationPrescribing azithromycinEvidence and evidence gaps in therapies of nasal obstruction and rhinosinusitis.Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungiInflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin.Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011Pseudomonas aeruginosa Acquisition in Cystic Fibrosis Patients in Context of Otorhinolaryngological Surgery or Dentist Attendance: Case Series and Discussion of Preventive Concepts.Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation.Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesiaAzithromycin use and outcomes in severe sepsis patients with and without pneumonia.Resistance-Nodulation-Division Multidrug Efflux Pumps in Gram-Negative Bacteria: Role in VirulenceRole of macrolide therapy in chronic obstructive pulmonary disease.Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts.Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.Antivirulence activity of azithromycin in Pseudomonas aeruginosaClarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control StudyAzithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.Cystic fibrosis: a clinical view.Best practices in the treatment of early cystic fibrosis lung disease.Phenotype-Driven Therapeutics in Severe Asthma.Azithromycin use in patients with cystic fibrosis.Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study.Macrolide resistance in pneumococci-is it relevant?Azithromycin attenuates acute radiation-induced lung injury in mice.Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial.Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms.Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstacles
P2860
Q24188139-BDD8CF5A-150B-4A8A-AA28-AB891614E155Q26471106-AEDD5922-553C-4E4E-96EB-9F572098391DQ26747065-3EB214CE-BDB6-4CCC-A980-91610A5BF776Q26749606-C932B33E-5898-447A-8625-FDE888614B61Q26773297-DF8EB11A-2726-4A81-9A6F-7829588C3FDEQ28069178-61B87621-0104-4FAE-8D85-BAD1C6BF2B79Q33792765-96092E1D-6F74-4D2F-B083-C5BECCA76D99Q33794333-2BEAD436-C3E7-41BB-9C2A-AD22FA6BD147Q34229701-70686769-E4AB-4F85-B0AB-A4200C711743Q34297656-99557372-6D7C-4555-856F-2AD5620B8FDEQ34732855-211C3E8A-9F0D-419F-B88A-B73C4CE48B60Q35239067-B3F2EA33-3A5D-4111-816B-1556E648E661Q35830510-669D8D5F-2A6B-49B5-A377-E24843898DC1Q35906474-E3D2F634-A1C4-485F-B71B-5AABB8B8E926Q36083767-8BB4BCF2-BBB0-409C-AA64-C5593F4ADBF1Q36626965-ABB2EBBE-9829-4787-A451-62B544764E9FQ36683498-B59793A1-BC0B-4021-857F-C83E310CF39CQ37319950-45442979-24D1-474A-A7B5-4EC9088C79BFQ37655419-36E43F30-CD6B-4C49-8063-AAB7704ECF28Q38177909-BA229CC7-FE2E-4550-910C-945B8301849BQ38209321-81EDFA3F-C998-4519-AC52-2A9BD601B2CEQ38374445-8817ABE4-8E12-4CE4-A926-010B3B279C83Q38529613-84F69720-5399-48FA-A63D-C465DEBE9E1FQ38973292-02122F73-224B-4CA8-9610-E4195515043EQ39028034-BA5CF613-55F6-4A9B-8273-1066FCD5DB01Q39148802-851C9A30-9925-4B8C-821C-802EE5645C96Q41428470-6E33BCEF-F9A7-481E-90E5-A0944ED521E1Q42075378-078E04E4-D910-4A6C-85AD-5FF716D28730Q42338498-9769FCF4-4E62-4DBD-87A1-0C9CCEEB6198Q43196038-BA1E3256-388F-4711-BCA6-05707C612B1BQ43538692-FAD6490C-2ACC-4AF1-9FA6-0DA88208DA88Q47134781-9C1100BB-B02D-49C2-B22A-09962F954041Q47136819-0B53D91B-7166-4C71-B155-B48F53608507Q47831284-E6AAA0EA-5EDE-4377-9776-357EE12115E3Q52721363-121D90EF-932A-444B-825D-C6AB6D8EC909Q54246461-8B0195E1-DDB6-4C13-B994-83C8C95F3218Q57300050-732A55C1-98BD-44D0-A23F-B278B6CA98CA
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Macrolide antibiotics for cystic fibrosis
@ast
Macrolide antibiotics for cystic fibrosis
@en
Macrolide antibiotics for cystic fibrosis
@en-gb
Macrolide antibiotics for cystic fibrosis
@nl
type
label
Macrolide antibiotics for cystic fibrosis
@ast
Macrolide antibiotics for cystic fibrosis
@en
Macrolide antibiotics for cystic fibrosis
@en-gb
Macrolide antibiotics for cystic fibrosis
@nl
prefLabel
Macrolide antibiotics for cystic fibrosis
@ast
Macrolide antibiotics for cystic fibrosis
@en
Macrolide antibiotics for cystic fibrosis
@en-gb
Macrolide antibiotics for cystic fibrosis
@nl
P2093
P2860
P3181
P1476
Macrolide antibiotics for cystic fibrosis
@en
P2093
Arturo Solis-Moya
Kevin W Southern
Latifa Patel
Pierre M Barker
P2860
P3181
P356
10.1002/14651858.CD002203.PUB4
P577
2012-11-14T00:00:00Z